Concord Biotech Limited, founded in 1984, is an India-based R&D-driven biopharma firm. In terms of market share, based on volume, the company is placed among the top global developers and manufacturers of certain fermentation-based APIs in immunosuppressants and oncology in 2022.
Concord Biotech has a global footprint. They sell their products in over 70 countries, including the United States, India, Europe, and Japan.
The company produces Active Pharmaceutical Ingredients (API) and completed formulations through fermentation and semi-synthetic processes. It began with a single product and has expanded to become a full-service solution supplier.
Concord produces fermentation and semi-synthetic-based products in therapeutic areas such as immunosuppressants, antibacterial agents, oncology agents, antifungals, and others. Customers from all around the world have been drawn to this diverse assortment of products. Concord also has a substantial product pipeline in the works.
Concord Biotech IPO Details
IPO Date | Aug 4, 2023 to Aug 8, 2023 |
Listing Date | [.] |
Face Value | Rs 1 per share |
Price | Rs 705 to ₹741 per share |
Lot Size | 20 Shares |
Total Issue Size | 20,925,652 shares (aggregating up to Rs 1,551.00 Cr) |
Offer for Sale | 20,925,652 shares of Rs 1 (aggregating up to ₹1,551.00 Cr) |
Employee Discount | Rs 70 per share |
Issue Type | Book Built Issue IPO |
Listing At | BSE, NSE |
Share holding pre issue | 104,616,204 |
Concord Biotech IPO Timetable
IPO Open Date | Friday, 4 August 2023 |
IPO Close Date | Tuesday, 8 August 2023 |
Basis of Allotment | Friday, 11 August 2023 |
Initiation of Refunds | Monday, 14 August 2023 |
Credit of Shares to Demat | Thursday, 17 August 2023 |
Listing Date | Friday, 18 August 2023 |
Concord Biotech IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Retail (Min) | 1 | 20 | Rs 14,820 |
Retail (Max) | 13 | 260 | Rs 192,660 |
S-HNI (Min) | 14 | 280 | Rs 207,480 |
S-HNI (Max) | 67 | 1,340 | Rs 992,940 |
B-HNI (Min) | 68 | 1,360 | Rs 1,007,760 |